A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Clinical trial NCT02158858 · COMPLETED

Trial details

NCT number: NCT02158858
Sponsor: Constellation Pharmaceuticals
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Myelofibrosis Leukemia, Myelocytic, Acute Myelodysplastic/Myeloproliferative Neoplasm Myelodysplastic Syndrome (MDS)Preleukemia Primary Myelofibrosis Myeloproliferative Disorders Bone Marrow Disease Hematological Disease Precancerous Conditions Neoplasms Leukemia

Start date: 2014-07-16
Primary completion: 2025-01-09
Enrollment: 336

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.